Targeted biologics, the recent emergence of innovative new oral therapies and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed. More than ever, for both existing brands & pipeline products, future success will require a deep understanding of this complex and rapidly evolving landscape.
In Immunology SGI focus on three key areas; Rheumatology, Dermatology and Gastroenterology, aiming to provide insight and answer critical questions such as….Which are the more dynamic brands across key auto-immune indications and why? How quickly are immune specialists adopting newly approved and novel treatments? What hopes and aspirations do prescribers have for novel MOAs? How do new approvals challenge the current treatment algorithm? How do perception of manufacturers and brand promotional activity influence prescribing behavior?
Direct from our Research!
Rheumatologists report significantly higher satisfaction with Cosentyx compared to Janssen’s Stelara with 46% stating the Cosentyx holds an efficacy advantage over Stelara.
Gastroenterologists identify the launch of Janssen’s Stelara as the most exciting thing to happen in IBD in 2016.
Among the pipeline agents for IBD, gastroenterologists are most familiar with Pfizer’s Xeljanz, an oral JAK-inhibitor already approved for rheumatoid arthritis. Oral agents hold massive appeal in the IBD market with up to one-third of the gastroenterologists willing to accept lower efficacy for the convenience of a pill.
Entyvio has developed a solid user base since launch.73% of gastroenterologists are using Entyvio in ten or more of their patients, a number equal to Remicade. This increasing depth of use should lead to increase for the brand in the 25% or more of patients moving forward.
In rheumatoid arthritis, with the introduction of sarilumab, a new IL-6 that will go head-to-head with Roche’s Actemra and Olumiant (the second JAK to hit the market) the alternative MOA market is likely to expand.